# Identification of potential drug-induced neuralgia signals through disproportionality analysis of the FAERS database

**Authors:** Yating An, Ying Zheng, Ziwei Jiang, Meng Meng, Jintuo Yin, Yahui An

PMC · DOI: 10.3389/fphar.2025.1645114 · 2025-07-30

## TL;DR

This study uses FAERS data to find drugs linked to drug-induced neuralgia, emphasizing the need for safer prescribing and further research.

## Contribution

The study identifies specific drugs and mechanisms associated with drug-induced neuralgia using disproportionality analysis of FAERS data.

## Key findings

- Lenalidomide showed the strongest association with neuralgia, followed by sodium citrate.
- Chemotherapeutics, antibiotics, and immunosuppressants were significantly linked to neuralgia.
- Neurotoxicity, immune mechanisms, and metabolic disruptions are potential causes of drug-induced neuralgia.

## Abstract

Drug-induced neuralgia is a common and significant adverse reaction. This study analyzed the United States food and drug administration adverse event reporting system (FAERS) database (2004–2024) to identify relevant drugs and potential mechanisms.

We conducted an association analysis between drugs and neuralgia using the FAERS database. Disproportionality analysis methods, including the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and empirical Bayesian geometric mean (EBGM), were applied. Data from 2004 to 2024 were analyzed to identify drugs potentially associated with neuralgia.

Among the 103,678 reports of neuralgia-related adverse events, 60.29% involved female patients, and 30.40% were aged between 41 and 64 years. The most common underlying medical conditions were plasma cell myeloma (14.28%) and multiple sclerosis (10.65%). The analysis revealed significant associations between neuralgia and several classes of drugs, including chemotherapeutic agents, certain antibiotics, and immunosuppressants, potentially attributable to neurotoxicity, immune-mediated mechanisms, or metabolic disruptions. Notably, lenalidomide exhibited the strongest association with neuralgia, followed by sodium citrate. These findings underscore the importance of early recognition, safer prescribing strategies, and further investigation to mitigate neurotoxic risks.

This study identifies key drugs, including chemotherapeutics, antibiotics, and immunosuppressants, associated with drug-induced neuralgia through FAERS data analysis, highlighting the need for early detection, safer prescribing practices, and further research into mitigating neurotoxicity.

## Linked entities

- **Chemicals:** lenalidomide (PubChem CID 216326), sodium citrate (PubChem CID 6224)
- **Diseases:** plasma cell myeloma (MONDO:0009693), multiple sclerosis (MONDO:0005301), neuralgia (MONDO:0021667)

## Full-text entities

- **Genes:** TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, TRPV1 (transient receptor potential cation channel subfamily V member 1) [NCBI Gene 7442] {aka VR1}, LINC-ROR (long intergenic non-protein coding RNA, regulator of reprogramming) [NCBI Gene 100885779] {aka ROR, lincRNA-RoR, lincRNA-ST8SIA3}
- **Diseases:** neuroinflammation (MESH:D000090862), Drug-induced neuralgia (MESH:D000081015), hypocalcemia (MESH:D006996), tissue injury (MESH:D017695), Pain (MESH:D010146), vascular and neurological diseases (MESH:D014652), Plasma cell myeloma (MESH:D009101), lymphoma (MESH:D008223), compression (MESH:D009408), Neuralgia (MESH:D009437), urinary tract infection (MESH:D014552), cancer (MESH:D009369), diabetes mellitus (MESH:D003920), nerve damage (MESH:D000080902), infections (MESH:D007239), ADEs (MESH:D064420), bleeding (MESH:D006470), nerve trauma (MESH:D020221), renal disease (MESH:D007674), metabolic disturbances (MESH:D024821), metabolic disruptions (MESH:D019958), death (MESH:D003643), multiple sclerosis (MESH:D009103), Anti (MESH:D006679), breast cancer (MESH:D001943), depression (MESH:D003866), disease in the nervous system (MESH:D009422), optic neuropathy (MESH:D009901), impaired neuronal function (MESH:D003072), mitochondrial dysfunction (MESH:D028361), neural damage (MESH:D015441), peripheral neuropathy (MESH:D010523), nociceptive pain (MESH:D059226), neurotoxic (MESH:D020258), metabolic disorders (MESH:D008659), numbness (MESH:D006987)
- **Chemicals:** paclitaxel (MESH:D017239), nelarabine (MESH:C104457), lazertinib (MESH:C000707992), fingolimod (MESH:D000068876), oxaliplatin (MESH:D000077150), vinca alkaloids (MESH:D014748), agents (-), nicotinic acid (MESH:D009525), bortezomib (MESH:D000069286), Lenalidomide (MESH:D000077269), gentamicin (MESH:D005839), platinum (MESH:D010984), fluoroquinolones (MESH:D024841), docetaxel (MESH:D000077143), ciprofloxacin (MESH:D002939), thalidomide (MESH:D013792), Sodium citrate (MESH:D000077559), taxanes (MESH:D043823), vincristine (MESH:D014750), heparin (MESH:D006493), teriflunomide (MESH:C527525), cisplatin (MESH:D002945), ethambutol (MESH:D004977), fumaric acid (MESH:C032005), clobetasone butyrate (MESH:C010893), sertaconazole (MESH:C061131), glucose (MESH:D005947), levofloxacin (MESH:D064704), gadofosveset (MESH:C109932), aminoglycosides (MESH:D000617), amikacin (MESH:D000583)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12343520/full.md

---
Source: https://tomesphere.com/paper/PMC12343520